Download or read book Diagnostic Prognostic and Predictive Factors of Response in the Era of Precision Oncology in Breast Cancer written by Francesco Schettini and published by Frontiers Media SA. This book was released on 2023-12-12 with total page 364 pages. Available in PDF, EPUB and Kindle. Book excerpt: In the last couple of decades, the study of the cancer genome and the progressive implementation of next-generation sequencing platforms have provided the Scientific and Oncology communities with a multitude of data, technologies, diagnostic, prognostic, and predictive tools that have been revolutionizing the way we can study, diagnose and treat cancer, including breast tumors. For example, genomic tests can now refine the prognosis of early-stage breast cancer patients beyond standard clinicopathological features and help guide escalated or de-escalated treatment choices. The identification of the molecular intrinsic subtypes might also be helpful in guiding treatment choices in advanced hormone receptor-positive disease. The identification of germline mutations in BRCA1 or BRCA2 has led to the development and introduction of PARP inhibitors for the treatment of advanced and early-stage breast cancer, along with personalized follow-up and prophylactic surgical procedures for patients with or without cancer, carrying such mutations.
Download or read book Translational Research in Breast Cancer written by Erwei Song and published by Springer. This book was released on 2017-12-28 with total page 418 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book offers a comprehensive introduction to translational efforts in breast cancer, addressing the latest approaches to precision medicine based on the current state of understanding of breast cancer. With the latest developments in breast cancer research, our understanding of the genomic changes and the oncogenic signaling cascade of breast cancer has made considerable strides. Further, the immuno-environment has been demonstrated as the barrier to clinical cancer. In addition, major advances in cancer biology, immunology, genomics and metabolism have broken new ground for designing therapeutic approaches and selecting appropriate treatments on the basis of more precise information on the individual patient. As a result of these two trends, a clearer picture of the molecular landscape of breast cancers has facilitated the development of diagnostic, prognostic and predictive biomarkers for clinical oncology. All these aspects are addressed in this volume, which offers a comprehensive resource for researchers, graduate students and oncologists in cancer research.
Download or read book Prognostic and Predictive Factors in Breast Cancer Second Edition written by Rosemary A. Walker and published by CRC Press. This book was released on 2003-06-12 with total page 232 pages. Available in PDF, EPUB and Kindle. Book excerpt: This title reviews the key prognostic factors in breast cancer, discussing the methodologies involved in measuring and reporting. It also examines the roles of major predictive markers such as the steroid receptors, p53 and HER-2. Given the wealth of information in the medical literature on breast cancer, this volume is useful in that it focuses strictly on these factors. That focus makes this text extremely useful for oncologists and researchers who want to learn more about best practices in prognoses.
Download or read book Biomarkers in Breast Cancer written by Giampietro Gasparini and published by Springer Science & Business Media. This book was released on 2008-01-17 with total page 335 pages. Available in PDF, EPUB and Kindle. Book excerpt: Expert laboratory and clinical researchers from around the world review how to design and evaluate studies of tumor markers and examine their use in breast cancer patients. The authors cover both the major advances in sophisticated molecular methods and the state-of-the-art in conventional prognostic and predictive indicators. Among the topics discussed are the relevance of rigorous study design and guidelines for the validation studies of new biomarkers, gene expression profiling by tissue microarrays, adjuvant systemic therapy, and the use of estrogen, progesterone, and epidermal growth factor receptors as both prognostic and predictive indicators. Highlights include the evaluation of HER2 and EGFR family members, of p53, and of UPA/PAI-1; the detection of rare cells in blood and marrow; and the detection and analysis of soluble, circulating markers.
Download or read book Prognostic and Predictive Factors in Breast Cancer written by Rosemary A Walker and published by CRC Press. This book was released on 2019-08-30 with total page 198 pages. Available in PDF, EPUB and Kindle. Book excerpt: This title reviews the key prognostic factors in breast cancer, discussing the methodologies involved in measuring and reporting. It also examines the roles of major predictive markers such as the steroid receptors, p53 and HER-2. Given the wealth of information in the medical literature on breast cancer, this volume is useful in that it focuses strictly on these factors. That focus makes this text extremely useful for oncologists and researchers who want to learn more about best practices in prognoses.
Download or read book High Risk Breast Cancer written by Joseph Ragaz and published by Springer Science & Business Media. This book was released on 2012-12-06 with total page 375 pages. Available in PDF, EPUB and Kindle. Book excerpt: The most meaningful reward to clinicians and researchers is the absence of recurrent malignancy in their patients. While in some patients the disease will be cured by resection alone, in other similarly staged cases the disease will recur despite adequate loco regional and systemic therapies. Hence, risk assessment is a complex issue with many related or unrelated prognostic factors determining outcome. The purpose of this volume is to review some of the most relevant prognostic factors of newly diagnosed breast cancer, focusing on fea tures determining the magnitude of risk. The ultimate value of establishing the significance of each prognostic factor in a given patient will be the resulting ability to plan individu alized therapies for patients at different risk of recurrence at the time of diagnosis. To secure the maximum benefit for high-risk patients, while avoiding undue toxicity in those with low-risk lesions, a well-integrated analysis of all known prognostic factors will be essential in the early postdiagnos tic period. In addition to well-established staging criteria such as axillary nodes, tumor size, receptors, scanning and radiographic examinations, the more sophisticated labora tory techniques, as discussed by several authors herein, will playa crucial role in risk assessment. Most of them, - ploidy determination, oncogenes, tumor markers, monoclonal anti bodies, growth factors, etc. -are presently available in only a minority of treatment centers.
Download or read book Prognostic variables in node negative and node positive breast cancer written by Giampietro Gasparini and published by Springer Science & Business Media. This book was released on 2012-12-06 with total page 416 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Breast Cancer Research and Treatment written by Ouissam Al Jarroudi and published by Springer Nature. This book was released on 2024-01-04 with total page 371 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book focuses on innovative treatment options for breast cancer, including surgery, radiotherapy, systemic therapy and of course immunotherapy that is changing outcomes in some aggressive breast cancer histotypes. Subsequent chapters also address the ongoing emerging research in the screening, diagnostics, and management of all subtypes of breast cancers. All current landscapes and future perspectives in each molecular subtype: luminal, HER2-positive, and triple-negative breast cancers are discussed within the different chapters. Breast cancer is still the most common cancer and cause of cancer deaths among women worldwide. The improvement of breast cancer outcome appears to be strictly related to the validation of precise biomarkers that enable us to better select personalized approaches in breast cancer management. The closing chapters deal with the challenges of conducting research in the era of precision medicine for cancer. The book is edited and authored by leading experts in this field and will be of interest for clinicians and scientists alike.
Download or read book Breast Cancer in the Post Genomic Era written by Antonio Giordano and published by Springer Science & Business Media. This book was released on 2009-06-22 with total page 237 pages. Available in PDF, EPUB and Kindle. Book excerpt: Breast Cancer is the most common tumor in women and the second leading cause of cancer deaths worldwide. Due to breakthroughs in gene profiling, the knowledge of the pathophysiology of the mammary gland had greatly increased over the last decade. In Breast Cancer in the Post Genomic Era, Antonio Giordano, Nicola Normanno, and a panel of international authorities in their field provide a comprehensive approach to the biology, diagnosis, prevention, and treatment of human breast carcinoma. The book provides a comprehensive approach to breast cancer, describing the use of gene profiling techniques to distinguish specific features of individual carcinomas, as well as emerging novel therapeutic approaches to treatment. Additional chapters cover the use of transgenic mice to model human breast cancer and the role of the EGF-CFC family in mammary gland development and neoplasia. Breast Cancer in the Post Genomic-Era succeeds in looking at breast cancer pathogenesis, diagnosis, and treatment under a more comprehensive light, and is a valuable resource for any Radiation or Surgical Oncologist, Cancer Biologist or Pathologist.
Download or read book Early Diagnosis and Treatment of Cancer Series Breast Cancer E Book written by Lisa Jacobs and published by Elsevier Health Sciences. This book was released on 2010-07-15 with total page 403 pages. Available in PDF, EPUB and Kindle. Book excerpt: Each volume in the Early Detection and Treatment of Cancer Series is packed with practical, authoritative information designed to cover the full range of diagnostic procedures, including pathologic, radiologic, bronchoscopic, and surgical aspects. You’ll be able to determine the safest, shortest, least invasive way to reach an accurate diagnosis; stage the disease; and choose the best initial treatment for early stages. Based on current evidence in the literature, authors provide clinical, hands-on tools to help you make informed decisions on precisely what tests and imaging studies are needed to diagnose and stage each type of cancer. Practical, authoritative, and highly-illustrated, this volume in the brand new Early Detection and Treatment of Cancer series covers current protocols and the latest advances in diagnostic imaging and molecular and serologic markers for breast cancer. Apply expert advice on the best “next-step plan for different presentations and tips for less invasive protocols. Get clinical, hands-on tools to help you make informed decisions on precisely what tests and imaging studies are needed for accurate diagnosis and staging. Clear figures, tables, and boxes illustrate step-by-step care of the full range of problems encountered. The small size and convenient format make this an ideal purchase for diagnostic reference. Outlines the steps after diagnosis to guide you through formulating a treatment or patient care plan. Emphasizes important points—such as the promising new breast cancer vaccine, sentinel node biopsy, and hormone receptor tests—with “key points boxes at the beginning of each chapter and pedagogic features throughout. Summarizes the process of accurately diagnosing and staging cancer in a logical, almost algorithmic, approach for easy reference. Discusses the treatment of early-stage disease so you have clear options for care. Complements the procedures outlined in the text with full-color photographs and line drawings to reinforce your understanding of the material.
Download or read book Long term Prognostic and Predictive Factors in Hormone Receptor Positive Breast Cancer written by Helena Fohlin and published by . This book was released on 2018 with total page 71 pages. Available in PDF, EPUB and Kindle. Book excerpt: The breast cancer survival in Sweden is good (almost 90 % 5-year relative survival) and has increased over time. For women with hormone receptor negative tumors, most relapses occur within the first 5 years after diagnosis. Thereafter the recurrence risk decreases rapidly. For women with estrogen receptor positive (ER+) tumors the annual risk for late recurrences is 1 – 2 %, even after 5 years of endocrine therapy. This risk accumulates so that approximately 25 % of the patients that are recurrence-free after five years from diagnosis may experience a relapse within further 15 years of follow-up. The relatively high long-term risk calls for identification of prognostic and predictive markers with long-term effect. Though, the number of such markers with proven significance is limited. Of the clinical characteristics, only nodal status and to some extent tumor size and tumor grade have been shown to have long-term prognostic value. In this thesis, we propose long-term prognostic and predictive markers for breast cancer. In paper I , we suggest the protein v-akt murine thymoma viral oncogene homologue 2 (AKT2) as a long-term prognostic marker among patients with ER+ tumors. In our study, besides nodal status, AKT2 was the only factor with long-term prognostic value. This is in accordance with some other studies, though we also showed that the significance of AKT2 was limited to ER+ tumors and that the impact increased with higher ER expression. Approximately 75 – 85 % of the ER+ tumors are also progesterone receptor positive (PR+). ER+/progesterone receptor negative (PR-) tumors are considered to be more aggressive and patients with such tumors are often treated with chemotherapy. In this group, more specific subgroups for targeted therapy are needed. Whereas ER has long been established as a predictive factor regarding tamoxifen benefit, the role of PR has not been clarified to date. In paper II , we showed that PR status adds predictive value to ER considering the long-term benefit from tamoxifen. In paper III , we aimed to identify new prognostic markers among patients with ER+ tumors. Systemically untreated patients with ER+/PR- tumors and high expression of the Ras-related protein RAB6C (RAB6C) had reduced distant recurrence rate. Therefore, we suggest RAB6C as a candidate marker for subgroup division among patients with ER+/PR- tumors. According to the results from paper II, there might be subgroups of patients with ER+/PRtumors that do benefit from tamoxifen. The aim of paper IV was to identify such subgroups. Here, we suggest that patients with ER+/PR- tumors and low RAB6C expression do benefit from tamoxifen. The results from this thesis may encourage further studies for more specific subgroup divisions. Such studies may lead to changes in the management program, where some patients with ER+ tumors should receive prolonged or more intense treatment and others reduced treatment based on the pathological markers AKT2, PR and RAB6C.
Download or read book Methods of Cancer Diagnosis Therapy and Prognosis written by M. A. Hayat and published by Springer Science & Business Media. This book was released on 2008-11-05 with total page 750 pages. Available in PDF, EPUB and Kindle. Book excerpt: The enormity of the global healthcare costs vical. One-fifth of all cancers worldwide as a result of cancer infliction cannot be are caused by a chronic infection, for overemphasized. There are more than 100 example, human papilloma virus (HPV) types of cancers; any part of the body can causes cervical cancer and hepatitis B be affected. More than 11 million people virus (HBV) causes liver cancer. Tobacco are diagnosed with cancer every year, and use is the most common preventable cause it is estimated that there will be 16 mil- of cancer in the world. Approximately, lion new cases per year by the year 2020. 168,000 cancer deaths are expected to be In 2005, 7. 6 million people died of can- caused by tobacco use. Approximately, cer, that is, 13% of the 58 million deaths 40% of cancer could be prevented, mainly worldwide. It is estimated that 9 million by not using tobacco, having a healthy people will die from cancer worldwide in diet, being physically active, preventing 2015 and 11. 4 million will die in 2030. infections that may cause cancer, reduc- More than 70% of all cancer deaths occur ing exposure to sunlight, and avoidance of in low and middle income countries. excessive alcohol consumption and stress Five major cancer causing overall mor- (anger). A third of cancers could be cured talities per year worldwide are (WHO): if detected early and treated adequately. It is well established that scientific 1. Lung: 1.
Download or read book Precision Medicine in Oncology written by Bulent Aydogan and published by John Wiley & Sons. This book was released on 2020-11-02 with total page 288 pages. Available in PDF, EPUB and Kindle. Book excerpt: A FRESH EXAMINATION OF PRECISION MEDICINE'S INCREASINGLY PROMINENT ROLE IN THE FIELD OF ONCOLOGY Precision medicine takes into account each patient's specific characteristics and requirements to arrive at treatment plans that are optimized towards the best possible outcome. As the field of oncology continues to advance, this tailored approach is becoming more and more prevalent, channelling data on genomics, proteomics, metabolomics and other areas into new and innovative methods of practice. Precision Medicine in Oncology draws together the essential research driving the field forward, providing oncology clinicians and trainees alike with an illuminating overview of the technology and thinking behind the breakthroughs currently being made. Topics covered include: Biologically-guided radiation therapy Informatics for precision medicine Molecular imaging Biomarkers for treatment assessment Big data Nanoplatforms Casting a spotlight on this emerging knowledge base and its impact upon the management of tumors, Precision Medicine in Oncology opens up new possibilities and ways of working – not only for oncologists, but also for molecular biologists, radiologists, medical geneticists, and others.
Download or read book Prognostic and Predictive Factors in Primary Breast Cancer written by Pierre Stefanus Gerardus Johannes Hupperets and published by . This book was released on 1995 with total page 143 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Molecular Oncology of Breast Cancer written by Jeffrey Stuart Ross and published by Jones & Bartlett Publishers. This book was released on 2005 with total page 536 pages. Available in PDF, EPUB and Kindle. Book excerpt: The first comprehensive reference to focus on the molecular development and treatment of the disease, Molecular Oncology of Breast Cancer provides authoritative information across the spectrum of modern breast cancer research and clinical care. Edited by two world-class experts in cancer pathology, drug development, and patient management, with contributions from over 50 experts, this ground-breaking text describes the genes, proteins, and biologic pathways that are being evaluated today and will be tested in the future to derive the molecular signature of each newly diagnosed breast cancer. For the first time, readers can now obtain, in a single volume, up-to-date information on how molecular-based tests are being used to identify predisposition, provide earliest detection, decide classification based on genetic fingerprint and predict therapy-specific outcomes. MOBC includes unique chapters on functional imaging and the impact of targeted therapies on the FDA approval process. This book gives readers vital, up-to-date information on important molecular discoveries that affect the everyday management of the breast cancer patient.
Download or read book Personalized Medicine in Oncology written by Ari VanderWalde and published by . This book was released on 2022 with total page 174 pages. Available in PDF, EPUB and Kindle. Book excerpt: Nowhere is the explosion in comprehensive genomic testing more evident than in oncology. Multiple consensus guidelines now recommend molecular testing as the standard of care for most metastatic tumors. To aid in the advancement of this rapidly changing field, we intend this Special Issue of JPM to focus on technical developments in the genomic profiling of cancer, detail promising somatic alterations that either are, or have a high likelihood of being, relevant in the near future, and to address issues related to the pricing and value of these tests.The last few years have seen the cost of molecular testing decrease by orders of magnitude. In 2018, we saw the first “site-agnostic” drug approvals in cancer (for microsatellite unstable cancer (PD-1 inhibitors) and NTRK-fusions (TRK inhibitors)). Research on targetable mutations, determination of genetic “signatures” that can use multiple individual genes/pathways, development of targeted therapy, and insight into the value of new technology remains at the cutting edge of research in this field. We are soliciting papers that present new technologies to assess predictive biomarkers in cancer, original research (pre-clinical or clinical) that demonstrates promise for particular targeted therapies in cancer, and articles that explore the clinical and financial impacts of this paradigmatic shift in cancer diagnostics and treatment.
Download or read book Clinical Performance of Diagnostic Prognostic and Predictive Immunohistochemical Biomarkers for Hormone Receptor negative Breast Cancer written by Jennifer Renae Won and published by . This book was released on 2015 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt:
